Antibacterial quality of some antibiotics available in five administrative areas along the national borders of Tanzania

References

• Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A. Drug shop regulation and malaria treatment in Tanzania – why do shops break the rules, and does it matter?. Health Policy Plan. 2007;22(6):393–403.
   Web of Science ®Google Scholar
• Verduin-Muttiganzi R, Verduin-Muttiganzi G. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1998;3(7):602.
   Web of Science ®Google Scholar
• Okonko IO, Soleye FA, Amusan TA, Ogun AA, Ogunnusi TA, Ejembi J. Incidence of multi-drug resistance (MDR) organisms in Abeokuta, Southwestern Nigeria. Global J Pharmacol. 2009;3(2):69–80.
   Google Scholar
• Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. ­Growing problem of multidrug-resistant enteric pathogens in Africa. Emerg Infect Dis. 2007;13(11):1640–1646.
   Web of Science ®Google Scholar
• Lahon K, Bairagi KK, Chaturvedi RK. Global scenario in counterfeit medicines: threat assessment, existing remedies and ­recommendations. Indian Journal of Public Health Research and Development. 2012;3(1).
   Google Scholar
• Wertheimer AI, Norris J. Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic. Res Social Adm Pharm. 2009;5(1):4–16.
   PubMed Web of Science ®Google Scholar
• Abubakar EMM. Antimicrobial susceptibility pattern of pathogenic bacteria causing urinary tract infections at the Specialist Hospital, Yola, Adamawa state, Nigeria. J Clin Med Res. 2009;1(1):1–8.
   PubMedGoogle Scholar
• Newton PN, Green MD, Fernández FM, Day NP, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6(9):602–613.
   PubMed Web of Science ®Google Scholar
• Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health. 2008;13(8):1062–1072.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother. 2007;60(2):214–236.
   PubMed Web of Science ®Google Scholar
• Liang BA. Fade to black: Importation and counterfeit drugs. Am J Law Med. 2006;32(2–3):279–323.
   Web of Science ®Google Scholar
• Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet. 2001;357(9272): 1933–1936.
   PubMed Web of Science ®Google Scholar
• Wan Po AL. Too much, too little, or none at all: dealing with substandard and fake drugs. Lancet. 2001;357(9272):1904.
   Web of Science ®Google Scholar
• Menkes DB. Hazardous drugs in developing countries. BMJ. 1997; 315(7122):1557–1558.
   Google Scholar
• Blomberg B. Antimicrobial Resistance in Bacterial Infections in Urban and Rural Tanzania [dissertation]. Bergen, Norway: University of Bergen; 2007.
   Google Scholar
• Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(Suppl 12):S122–S129.
   PubMed Web of Science ®Google Scholar
• Newton PN, Green MD, Fernández, FM. Impact of poor-quality medicines in the ‘developing’ world. Trends Pharmacol Sci. 2010;31(3): 99–101.
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
   PubMed Web of Science ®Google Scholar
• Mwambete KD. Irrational antibiotic usage in boarding ­secondary school settings in Dar es Salaam. East Afri J Public Health. 2009;6(2): 200–204.
   Google Scholar
• Fehintola FA. Pre-hospital and prescription use of antibacterial drugs at a secondary health centre in Ibadan, Nigeria. Afri J Pharm Pharmacol. 2009;3(4):120–123.
   Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in ­Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43 Suppl 2:S49–S56.
   Google Scholar
• Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother. 2007;51(11):4062–4070.
   PubMed Web of Science ®Google Scholar
• Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ Jr, ­Bennish ML. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ. 1995;311(6997):88–91.
   PubMedGoogle Scholar
• Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2(9):839–845.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 16th Informational ­Supplement. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI) ­document M100-S16; 2006.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: 12th Informational Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards (NCCLS) document M100-S12; 2002.
   Google Scholar
• Cheesbrough M. Antimicrobial sensitivity testing, in District ­Laboratory Practice in Tropical Countries. Cambridge, UK: Cambridge University Press; 2006.
   Google Scholar
• Hogerzeil HV, de Goeje MJ, Abu-Reid IO. Stability of essential drugs in Sudan. Lancet. 1991;338(8769):754–755.
   Web of Science ®Google Scholar
• Arya SC. Inadvertent supply of substandard drugs. World Health Forum. 1995;16(3):269.
   Google Scholar
• Moken MC. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices. Am J Law Med. 2003;29(4):525–542.
   Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet] General ­information on counterfeit medicines [updated 2014; cited May 23, 2014]. Geneva, Switzerland: World Health Organization; 2014. Available from: http://www.who.int/medicines/services/counterfeit/overview/en. Accessed May 23, 2014.
   Google Scholar
• Late SG, Yu YY, Banga AK. Effects of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets. Int J Pharm. 2009;365(1–2):4–11.
   Google Scholar
• Jivraj M, Martini LG, Thomson CM. An overview of the different excipients useful for the direct compression of tablets. Pharm Sci Technol Today. 2000;3(2):58–63.
   PubMedGoogle Scholar
• Holford, NHG. Rational dosing and time course of drug action. In: Katzung BG, Masters SB, Trevor AJ, editors. Pharmacokinetics and Pharmacodynamics. 11th ed. San Francisco: McGraw-Hill Companies; 2009:34–50.
   Google Scholar
• Marais AF, Song M, de Villiers MM. Effect of compression force, humidity and disintegrant concentration on the disintegration and dissolution of directly compressed furosemide tablets using croscarmellose sodium as disintegrant. Trop J Pharm Res. 2003;2(1):125–135.
   Google Scholar
• Ekedahl AB. Reasons why medicines are returned to Swedish pharmacies unused. Pharm World Sci. 2006;28(6):352–358.
   PubMedGoogle Scholar
• Ette EI. Conscience, the law, and donation of expired drugs. Ann Pharmacother. 2004;38(7–8):1310–1313.
   Web of Science ®Google Scholar
• Lyon RC, Taylor JS, Porter DA, Prasanna HR, Hussain AS. Stability profiles of drug products extended beyond labeled expiration dates. J Pharm Sci. 2006;95(7):1549–1560.
   Web of Science ®Google Scholar
• [No authors listed]. Drugs past their expiration date. Med Lett Drugs Ther. 2009;51:100–101.
   Web of Science ®Google Scholar
• Lohiya S. A simple stratification and storage system for samples and supplies. J Natl Med Assoc. 2006;98(3):405–407.
   Web of Science ®Google Scholar
• Cohen JC, Mrazek M, Hawkins L. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction. Clin Pharmacol Ther. 2007;81(3):445–449.
   Web of Science ®Google Scholar